Celares GmbH
Home  |  Contact  |  Imprint
celares GmbH celares GmbH celares GmbH celares GmbH celares GmbH
 
 
 

News release

News release

Merck Millipore and celares GmbH
announce collaboration

New: Discrete 4-arm-PEG Maleimide

New: Discrete 4-arm-PEG Maleimide

The multimerisation with discrete 4-arm PEG facilitates defined linker lenght according to binding requirments

Hydrophilic linkers for ADCs

Hydrophilic linkers for ADCs

celares PEG based linker increase solubility of hydrophobic cytotoxic drugs

PEG-peptide conjugates

Multiple sclerosis (MS) is the most common non-traumatic disorder of the central nervous system (CNS) in young adults. It is commonly viewed as an autoimmune disease that targets and causes damage to the myelin sheath and the underlying neuron. Clinical manifestation is usually characterized by recurrent neurological attacks followed by periods of remission. Current therapies are based on unspecific immune modulating effects and are only treating symptoms.

Together with the group of Professor Alf Hamann

Efficacy of pMOG-PEG in EAE mice. Animals were treated with pMOG, pMOG-PEG or PBS prior to induction of EAE. The clinical score was monitored for 32 days. Efficacy of pMOG-PEG in EAE mice. Animals were treated with pMOG, pMOG-PEG or PBS prior to induction of EAE. The clinical score was monitored for 32 days.
 
Federal Ministry of Economics and Technology Federal Ministry of Economics and Technology

from the German research centre for rheumatology (DRFZ) celares GmbH is developing a novel treatment for MS. The aim of the project is to develop PEG-peptide conjugates for the induction of selective tolerance towards CNS-associated antigens. The project has been funded by the Bundesministerium für Wirtschaft und Technolgoie aufgrund eines Beschlusses des Deutschen Bundestages.

First results in animal experiments are very promising. Mice with Experimental Autoimmune Encephalomyelitis (EAE) that were treated with pMOG-PEG showed significantly lower clinical scores than those treated with the unmodified peptide or a PBS control.

The use of PEG-peptides for the treatment of MS is covered by patent application EP11177110.1.